Literature DB >> 23537500

NMDA receptor-dependent function and plasticity in inhibitory circuits.

Alexandre W Moreau1, Dimitri M Kullmann.   

Abstract

NMDA receptors have been known to play a central role in long-term potentiation at glutamatergic synapses in principal cells for thirty years. In contrast, their roles in the development and activity-dependent plasticity of synapses in inhibitory circuits have only recently begun to be understood. Progress has, to a great extent, been hampered by the extensive diversity of GABAergic cell types in the CNS. However, anatomical, immunohistochemical and electrophysiological methods have allowed distinct types to be identified, with the result that consistent patterns of synaptic plasticity have begun to emerge. This review summarizes recent evidence on the role of NMDA receptors in the development and plasticity of GABAergic synapses on principal cells and of glutamatergic synapses on identified interneurons. A major challenge is to understand how NMDA receptors affect the routing of information in healthy inhibitory circuits, and how changes in NMDA receptor function may contribute to altered circuit function in disorders such as schizophrenia. This article is part of the Special Issue entitled 'Glutamate Receptor-Dependent Synaptic Plasticity'.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inhibitory circuits; Interneurons; NMDA receptors; Plasticity; Schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 23537500     DOI: 10.1016/j.neuropharm.2013.03.004

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  20 in total

Review 1.  The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.

Authors:  Samuel M Cohen; Richard W Tsien; Donald C Goff; Michael M Halassa
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

Review 2.  Hippocampal GABAergic Inhibitory Interneurons.

Authors:  Kenneth A Pelkey; Ramesh Chittajallu; Michael T Craig; Ludovic Tricoire; Jason C Wester; Chris J McBain
Journal:  Physiol Rev       Date:  2017-10-01       Impact factor: 37.312

3.  Evidence for inhibitory deficits in the prefrontal cortex in schizophrenia.

Authors:  Natasha Radhu; Luis Garcia Dominguez; Faranak Farzan; Margaret A Richter; Mawahib O Semeralul; Robert Chen; Paul B Fitzgerald; Zafiris J Daskalakis
Journal:  Brain       Date:  2014-12-17       Impact factor: 13.501

Review 4.  The Gut-Brain Axis, BDNF, NMDA and CNS Disorders.

Authors:  Raeesah Maqsood; Trevor W Stone
Journal:  Neurochem Res       Date:  2016-08-23       Impact factor: 3.996

5.  Enriched environment prevents cognitive and motor deficits associated with postnatal MK-801 treatment.

Authors:  Masoumeh Nozari; Mohammad Shabani; Mahdieh Hadadi; Nafiseh Atapour
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

6.  Olanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens.

Authors:  Su Xu; Rao P Gullapalli; Douglas O Frost
Journal:  Schizophr Res       Date:  2014-12-05       Impact factor: 4.939

Review 7.  The origin of NMDA receptor hypofunction in schizophrenia.

Authors:  Kazu Nakazawa; Kiran Sapkota
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310

Review 8.  NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.

Authors:  Melissa A Snyder; Wen-Jun Gao
Journal:  Schizophr Res       Date:  2019-04-09       Impact factor: 4.939

Review 9.  Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.

Authors:  Felipe V Gomes; Anthony A Grace
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

10.  The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment.

Authors:  Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro; Andrea de Bartolomeis
Journal:  Curr Neuropharmacol       Date:  2014-05       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.